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Abstract
Background: Clinical studies have shown an association between long-term anticholinergic (AC) drug exposure
and Alzheimer’s disease (AD) pathogenesis, which has been primarily investigated in Parkinson’s disease (PD).
However, long-term AC exposure as a risk factor for developing neurodegenerative disorders and the exact
mechanisms and potential for disease progression remain unclear. Here, we have addressed the issue using
trihexyphenidyl (THP), a commonly used AC drug in PD patients, to determine if THP can accelerate AD-like
neurodegenerative progression and study potential mechanisms involved.
Methods: Male Sprague-Dawley rats (SD) were intraperitoneally injected with THP (0.3 and 1.0 mg/kg) or normal
saline (NS) for 7 months. Alterations in cognitive and behavioral performance were assessed using the Morris water
maze (MWM) and open field tests. After behavior tests, whole genome oligo microarrays, quantitative real-time reverse
transcription-polymerase chain reaction (qRT-PCR), immunohistochemistry, and immunofluorescence-confocal were
used to investigate the global mechanisms underlying THP-induced neuropathology with aging.
Results: Compared with NS controls, the MWM test results showed that THP-treated rats exhibited significantly
extended mean latencies during the initial 3 months of testing; however, this behavioral deficit was restored between
the fourth and sixth month of MWM testing. The same tendencies were confirmed by MWM probe and open field
tests. Gene microarray analysis identified 68 (47 %) upregulated and 176 (53 %) downregulated genes in the
“THP-aging” vs. “NS-aging” group. The most significant populations of genes downregulated by THP were the immune
response-, antigen processing and presentation-, and major histocompatibility complex (MHC)-related genes, as
validated by qRT-PCR. The decreased expression of MHC class I in THP-treated aging brains was confirmed by confocal
analysis. Notably, long-term THP treatment primed hippocampal and cortical microglia to undergo an inflammatory
phenotypic switch, causing microgliosis and microglia activation, which were positively accompanied by pathological
misfolded tau lesions.
Conclusions: Our findings suggest that immune response and neuroinflammation represent a pivotal mechanism in
THP-induced AD-like neuropathology processes with long-term exposure to AC drugs.
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Background
Negative cognitive effects are known to be an adverse ef-
fect of anticholinergic (AC) drugs and are assumed to be
transient and reversible [1–3]. However, there is a new
emerging hypothesis for the connection between AC ex-
posure and pathogenesis of Alzheimer’s disease (AD),
with the primary clinical lead for this connection being
Parkinson’s disease (PD) [4, 5]. Trihexyphenidyl (THP) is
the most commonly used AC drug in PD patients. Perry
et al. found that continuous THP use for at least 2 years
doubled the prevalence of both amyloid plaque and
neurofibrillary tangle densities in PD patients [4–6]. Fur-
thermore, some animal studies demonstrated that use of
ACs increased Aβ peptide presence in the cortex and
hippocampus, while selective M1 agonists are efficacious
for AD treatment [7, 8]. Therefore, duration of AC drug
administration has been described as a risk factor for
appearance of dementia in PD patients. Despite early
epidemiological evidence supporting this hypothesis in
the clinic, understanding of the impact of ACs on
pathogenesis of neurodegeneration is currently limited.
In particular, it is not clear whether the onset of events
that results in AC administration is part of aging or re-
flects early AD development. Understanding such pro-
cesses is vital as most drug therapies involve chronic
administration.
In the current study, we examined the hypothesis that
duration of AC drug exposure affects progression of
central nervous system (CNS) neurodegeneration. We
treated rats with THP (0.3 or 1.0 mg/kg/day, intraperito-
neal (IP)) for 7 months; these concentrations have proven
successful in previous studies [9, 10]. Administration was
started in 3-month-old normal Sprague-Dawley (SD) rats,
while the control group was provided with normal saline
(NS) only. Behavioral performance was assessed using the
Morris water maze (MWM) and open field tests. Add-
itionally, after behavioral testing, whole genome oligo mi-
croarrays and quantitative real-time reverse transcription-
polymerase chain reaction (qRT-PCR) were performed in
the hippocampus to gain insight into the global gene ex-
pression and pathway responses to long-term THP expos-
ure. Further, the cerebral cortex and hippocampus were
histologically examined for associated neurodegeneration.
We found that THP treatment altered neuroimmune re-
sponses and promoted CNS neuroinflammation features
consistent with microgliosis and microglia activation. We
believe that such detailed information is critical for under-
standing the long-term effects of ACs on occurrence or
earlier development of AD.
Methods
Chemicals
Trihexyphenidyl (THP) hydrochloride was purchased
from Sigma (St. Louis, MO, USA). All drugs were
dissolved or diluted in NS, and solutions adjusted to a
pH range of 6.5–7.0 for IP injections.
Animals and experimental design
Adult male SD rats (180–200 g) were supplied by the
Animal Center of the Academy of Military Medical
Science (Beijing, China). All rats were kept in plastic
cages and received food and water ad libitum. The
colony room was maintained at 22–23 °C and kept on a
12-h light/dark cycle. All testing was performed under
the guidelines for the use of experimental animals of the
Beijing Local Committee on Animal Care and Use.
Long-term THP treatment
Long-term THP treatment was initiated at 3 months of
age (n = 10 per group). Each rat was given a single IP in-
jection of THP (0.3 or 1.0 mg/kg/day) in a volume of
0.1 ml/100 g body weight. Controls received an equiva-
lent volume of NS. Treatment was maintained during
behavioral testing. Figure 1 schematically depicts the
experimental timeline. After injection, animals were




A MWM apparatus (Chengdu Technology & Market
Co. Ltd., Chengdu, China) was used to test spatial learn-
ing and memory, as previously described [11], with
minor modifications. Briefly, the animals received three
trials per day for 7 days to learn the task. Each trial
lasted until the animal found the platform or for a max-
imum of 120 s. Animals that failed to find the platform
within 120 s were guided there by the experimenter.
After the learning trail, rats were assigned to THP-
treated (0.3 or 1.0 mg/kg; n = 10 per group) or NS-treated
(n = 10) groups based on the same average escape time to
reach the platform. For subsequent navigation tests, the
animals underwent six consecutive training sessions for
6 months. For each training session, the animals received
three trials per day for 7 days at the beginning of each
month. On each trial, rats were placed into the pool facing
the wall, with start locations varied across trials and days.
The time taken to reach the platform was recorded as the
escape latency(s). During the navigation test, escape la-
tency to the platform for all trials was recorded. Spatial
learning ability was determined by the average escape la-
tency to the platform in every session. Swimming speed
was averaged according to the last trial.
The probe trial was performed three times within
1 week following the final day of navigation training. On
the day of testing, animals were given a probe trial, with
the platform removed. All trials were recorded for 60 s
using a digital camera. Additionally, the time spent in
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each target quadrant, as well as the number of annulus
crossings (defined as the circular zone surrounding the
platform position) was recorded to evaluate spatial
memory ability. All training took place during the light
phase, between 8:00 AM and 12:00 PM (lights on at
6:00 AM).
Open field activity
After completion of the MWM test, the animals were
given 1 week of rest, and then spontaneous activity was
assessed using a Digiscan Animal Activity Monitor sys-
tem for 5 min (Jiliang Software Technology Co., Ltd.,
Shanghai, China), as described previously [12]. Each ac-
tivity unit contains 16-photo beams positioned 5 cm
apart: 8 on the X-axis and 8 on the Y-axis. The Digiscan
analyzer was interfaced with an IBM XT computer using
JLBehv software (Jiliang Software Technology Co., Ltd.).
On the day of testing, the rats were transferred from the
animal colony into the laboratory and allowed to habitu-
ate for 120 min before testing. Total movement activity
was recorded for each experiment. Inner or outer time
measures the proportion of time spent in the center or
outer of the arena, respectively (i.e., percentage of total
time).
RNA extraction and microarray analysis
All samples were hybridized onto the Whole Rat
Genome Oligo Microarray (Agilent Technologies,
Madrid, Spain) encompassing more than 44,000 rat
DNA probes. Protocols for the sample preparation and
hybridization were adapted from the Agilent Technical
Manual. RNA extraction and microarray analysis were
performed as described previously [13]. RNA was iso-
lated using the Qiagen RNeasy Mini Kit for animal tis-
sues (Qiagen, Inc., Valencia, CA, USA). RNA quality and
quantity was checked using the Agilent 2100 bio-
analyzer and by running RNA sample aliquots on the
Affymetrix Gene Chip (Agilent Technologies). Total
RNA was used to generate biotin-labeled cRNA using
the MessageAmp™ Premier RNA Amplification Kit
(cat #1972; Ambion, Austin, TX, USA). A total of
0.75 μg of biotin-labeled cRNA was hybridized onto
chips by incubating at 65 °C for 17 h with constant
rotation using the Eukaryotic Hybridization Control
Kit (Affymetrix, San Diego, CA, USA). Arrays were
washed, blocked, and labeled cRNA detected by staining
with Fluidics Station 450/250 Cocktail (Affymetrix).
Arrays were scanned using an Affymetrix GeneChip®
Scanner 3000, and image data extracted using AGCC
Software (Affymetrix GeneChip Command Console® Soft-
ware). All results were given as gene expression ratio
(ratio of Cy3 to Cy5 intensity). Functional annotations (in-
cluding Gene Ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways) were analyzed
using the Molecule Annotation System (MAS) functional
tool (http://bioinfo.capitalbio.com/mas3/). To detect
THP-responsive genes, biological pathways that were
likely to be involved in THP action in the nervous system
were identified using typical criteria (fold change >2).
These genes were then assigned to relevant GO biological
pathways and KEGG molecular pathways by MAS. Re-
lated, significant GO biological pathways were identified
by EASE score P values <0.01, while significant KEGG
molecular pathways were identified using EASE score P
values <0.05. Accordingly, higher enrichment and gene
counts deemed that the genes of these pathways were
more important.
Quantitative real-time reverse transcription-polymerase
chain reaction
To verify the cDNA microarray results, qRT-PCR was
performed for six selected genes: MHC class I RT1.Ac
heavy chain, signal peptide (RT1-CE12); histocompati-
bility 2, class II antigen E alpha (R-H2Ea), class II in-
variant chain (Cd74), major histocompatibility
complex, class I-related (Mr1); and collagen, type I,
alpha 2 (COL1a2), and MHC class I RT1 class Ib,
locus Aw2 (RT1-AW2). Real-time PCR was performed
with the primers listed in Table 1 as described previ-
ously [14], qRT-PCR was performed using the Light
Fig. 1 Study timeline. Study consisted of long-term THP treatment, in which male SD rats received THP (0.3 or 1.0 mg/kg/day, IP) or control solution (NS)
for an average period of 7 months, beginning at 3 months of age. Rats first underwent the MWM navigation test during the 6-month THP treatment. After
the last navigational training test, probe test were performed three times within 1 week. After a 1-week interval, the open field test was then performed.
After completion of behavioral testing, the rats were sacrificed for microarray, immunohistochemistry, immunoblotting, and quantitative real-time reverse
transcription-polymerase chain reaction (qRT-PCR) analyses
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Cycler FastStart DNA Master SYBR Green I kit (Roche
Diagnostics, Mannheim, Germany), according to the
manufacturer’s instructions, on a Roche Light Cycler
platform (Roche, Göttingen, Germany). cDNA was
used for each analyzed sample. A calibration curve
was included in each experiment (four serial dilu-
tions). Final products were analyzed using the pro-
vided software (Roche Molecular Biochemicals
LightCycler Software v3.5). Melting curves occurred at
95 °C for 60 s and 55 °C for 30 s. All quantifications
were normalized to the β-actin gene. The six genes
(RT1-EC12, R-H2Ea, Mr1, Cd74, Colla2, and RT1-
AW2) were chosen for qRT-PCR validation according
to the criteria of (1) high within-group homogeneity of
microarray values and high fold change (FC > |2|) or
(2) known major histocompatibility complex (MHC)-
relative immune function.
A non-template control with non-genetic material was
included to eliminate contamination or nonspecific reac-
tions. Each sample (n = 4) was tested in triplicates and
then used for the analysis of relative transcription data
using the 2−ΔΔCT method (Table 1).
Immunohistochemistry and immunofluorescence
Paraffin wax-embedded rat brain sections (4 μm thick)
were dewaxed in xylene (three times for 3 min) and
rehydrated in decreasing concentrations of ethanol
(100 % twice, 96 %, 70 % ethanol, and H2O twice for
3 min each), followed by washing for 5 min in 50 mM
Tris-buffered saline (TBT) (pH 7.4). Optimal antigen
retrieval was achieved by treating sections for 5 min
with a citrate buffer (0.1 M citric acid and 0.1 M tri-
sodium citrate-2-hydrate [15]) and microwaving at
84 °C followed by pepsin treatment, as described.
Before primary antibody incubation, sections were
treated for 1 h with blocking solution (phosphate-buffered
saline (PBS) (pH 7.4) containing 5 % normal horse serum,
5 % normal goat serum, and 4 % BSA). Primary antibodies
were diluted in PBS (pH 7.4; with 2.5 % normal horse
serum, 2.5 % normal goat serum, and 2 % BSA).
Cortical or hippocampal sections from rats were in-
cubated overnight at 4 °C in a moist chamber with
rabbit CD11b (1:100), goat anti-Iba1 (1:100), rabbit p-tau
AT270 (p-T181) (1:300), and phospho-tau AT8 (p-S202/
T205) (1:300) in TBS-T with 1 % BSA. After a further
round of washing with TBS-T, sections were incubated
with DAB-conjugated secondary antibodies (1:250;
Jackson ImmunoResearch, Bar Harbor, ME, USA) for
1 h in a moist chamber at room temperature. All anti-
bodies were purchased from Abcam (Shanghai, China).
Slides were then rinsed in TBS-T, mounted in a mix of
glycerol/PBS (3:1), and observed using an inverted micro-
scope (Nikon eclipse TS100, Nikon, Tokyo, Japan)
equipped with a digital camera (DXM1200F).
For immunofluorescence staining, cortical or hippo-
campal sections were collected consecutively, and then
incubated overnight at 4 °C with anti-rat MHC class I
(MHCI) (ER-HR52) (1:100), mouse anti-NeuN (1:200),
rabbit anti-M1 receptor (1:100), and mouse CD68
(1:100) (Abcam). After washing with PBS, sections
were incubated with FITC-Green 488- or TRITC-Red
595-conjugated secondary antibody (1:500) for 2 h at
37 °C. Images were observed by laser confocal micro-
scope (LSM710; Zeiss, Germany). Cropping of images
and adjustment of brightness and contrast were iden-
tical for each staining and performed using Adobe
Photoshop CS5 software (Adobe Systems, San Jose,
CA, USA).
Table 1 Sequence of specific primers used for quantitative real-time PCR (qRt-PCR)
Gene ID Primer Pair sequences (5′-3′) Length (bp)
NM_031144 R-β-actin-S TGCTATGTTGCCCTAGACTTCG 240
R-β-actin-A GTTGGCATAGAGGTCTTTACGG
NM_012645.1 R-RT1-AW2-S TGGGCTTCTACCCTGCTGACA 138
R-RT1-AW2-A CAAGAGGCACCACCACAGATG
NM_001008847.2 R-H2Ea-S TCCACTATCTGACCTTCCTGCC 129
R-H2Ea-A CTTTAGTTTCTGGGAGGAGGGTT
NM_001100635.1 R-MR1-S CGGGTGACGCTGTCGTATGTAG 172
R-MR1-A TGTTCCTGCTACCGTTCCTCAC
NM_001008835 R-RT1-CE12-S TGAACCTGAGGACACTGCTTGG 218
R-RT1-CE12-A CTCCCACTTGTTTCGGGTCATC
NM_053356.1 R-Col1a2-S GTGCCTAGCAACATGCCAATCT 207
R-Col1a2-A TGAGCAGCAAAGTTCCCAGTAAG
NM_013069.2 R-CD74-S TCTGGACTGGAAGGTCTTTGAG 162
R-CD74-A CCCATATCCTGCTTGGTCACT
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Immunoblotting
Equal protein amounts were separated on 4–12 % SDS-
PAGE gradient gels, transferred to nitrocellulose mem-
branes, and incubated overnight with primary antibody
at 4 °C. The following primary antibodies were used:
phospho-tau AT8 (p-S202/T205) (1:1000), p-tau AT270
(p-T181) (1:1000), CD11b (1:1000), and CD68 (1:1000).
After washing, membranes were incubated with second-
ary antibody coupled to horseradish peroxidase. Immu-
nocomplexes were visualized using the Super Signal
West Pico Kit from GE Healthcare (Amersham). Band
density measurements were obtained using ImageJ 1.36b
imaging software (National Institutes of Health,
Bethesda, MD, USA).
Gallyas silver staining
To identify mature neurofibrillary pathology in neurons,
Gallyas silver iodide staining was performed [16]. Sec-
tions were examined using an Olympus BX51 micro-
scope and photographed using an Olympus camera DP-
50 (Olympus, Japan).
Fluoro-Jade B staining
A commercial Fluoro-Jade B (FJB) kit (Millipore, Billerica,
MA, USA) was used to detect dystrophic neuritis. Tissue
sections processed for anti-NeuN immunofluorescence
were mounted on gelatin-coated slides, air dried for 2–
3 h, and then FJB stained in accordance with the manufac-
turer’s protocol. In brief, slides were incubated in a 0.06 %
potassium permanganate solution for 10 min, followed by
a 0.0004 % FJB solution for 30 min. Sections were washed
three times in distilled water, fully dried, and cleared in xy-
lene. Slides were coverslipped using aqueous mounting
medium containing DAPI (Dako, Glostrup, Denmark) and
examined under a confocal laser scanning microscope.
After immersion in xylene, integrated immunofluores-
cence density analysis was performed using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA).
The integrated pixel density was measured in three ran-
dom areas from each slide (four slides in total). The aver-
age integrated pixel density was calculated for each slide
and each group, and then compared.
Statistical analysis
All data were expressed as mean ± S.D. Student’s t tests
were used to determine differences between the two ex-
perimental groups, while one-way or two-way analysis of
variance (ANOVA) was used to compare differences be-
tween three or more groups for individual group com-
parisons. Data were analyzed using GraphPad Prism 5.0
software (GraphPad Software Inc., San Diego, CA). The
accepted level of significance for all tests was P < 0.05.
Results
Cognitive behavioral impairment is present during early
THP treatment.
The effect of long-term THP treatment on cognitive
capacity of the aging rat was assessed using the MWM
test. THP (0.3 and 1.0 mg/kg/day) was administered in-
traperitoneally for 6 months to determine its long-term
effect on memory deficits. The MWM test was initiated
at 3 months of age. Age-matched, NS-treated littermates
were maintained as the control group. Rats at 3 and
9 months of age were treated as younger and aging rats,
respectively, in our study (Fig. 2a). Their performance in
the MWM task is shown (Fig. 2). As shown in Fig. 2b,
NS-treated littermates showed a typical reduction in es-
cape latency time at the beginning of 3 months of train-
ing (Fig. 2b), while THP-treated rats showed cognitive
impairment, as indicated by longer latencies to find the
platform. Accordingly, THP (1.0 mg/kg/day) significantly
extended the time to find the escape platform at the 2-
month (t [10] = 9.226, P < 0.001) and 3-month (t [10] =
5.539, P < 0.001) training sessions. However, upon repeti-
tion of training in the subsequent trials at 4 to 6 months,
THP-treated rats showed a progressive reduction in the
time to reach the escape platform, with the escape la-
tency reduced to the same level as NS control rats (ap-
proximately 7.02 ± 1.44 s) (Fig. 2b). At the end of
navigation training, swimming speed was not signifi-
cantly different between groups (Fig. 2b). After removal
of the hidden platform, a 60-s probe trial was performed
to assess the animal’s memory for the platform location.
THP (0.3 mg/kg) slightly increased the number of plat-
form crossings, and one-way repeated measures ANOVA
revealed a significant group effect (F [1, 10] = 4.6,
P < 0.05; Fig. 2d). The time spent in the relevant quadrant
zone during the probe trial for NS-treated rats was
67.22 ± 2.5 %, whereas for THP-treated rats was
slightly more specific (70.88 ± 7.26 % for 1.0 mg/kg
and 74.98 ± 6.27 % for 0.3 mg/kg; Fig. 2e). These find-
ings indicate that THP-treated rats effectively retained
memory of the platform position at the end of the
MWM test.
After a 1-week rest interval, the animals were then fur-
ther tested using the open field activity test. Their loco-
motor activity is shown (Fig. 3a, b). There was no
significant change in total movement in the THP group
compared with the NS group. All groups travelled simi-
lar distances and spent more than half the time in the
outer zone and less than 10 % of the time in the center
of the apparatus during the 5-min test period.
THP affects neuroimmune/neuroinflammation genomic
transcription patterns after long-term exposure
After behavioral testing, hippocampal gene expression
profiles were determined by microarray analysis. From a
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Fig. 2 Effect of THP on learning and memory in SD rats after 6 months of treatment. a Three- and 9-month-old rats were tested in the MWM.
b THP/NS effects on MWM platform acquisition measured by escape latency (in seconds). The effect on platform escape latency was measured
for 7 days at the beginning of every month over 6 months of MWM testing. c THP/NS effect on swimming speed when searching for the MWM
platform. d THP/NS effect on number of platform crosses during the three-probe trial time period after MWM acquisition. e THP/NS effect
on time spent in the MWM platform quadrant during the three-probe trial time period after MWM acquisition. The THP (0.5 mg/kg) group spent
significantly more time in the MWM platform quadrant. For this and subsequent analyses, histogram values represent mean ± SD (n = 10). *P < 0.05,
**P < 0.01, ***P < 0.001
Fig. 3 THP/NS effect on open field test performance. a Total count for movement activity. b Travelled time spent in specific zones of the
apparatus. The THP group displayed similar behavior with no difference between groups in terms of movement activity (mean ± SD, n = 10)
Huang et al. Journal of Neuroinflammation  (2016) 13:175 Page 6 of 16
total of 31,043 genes, log-log scatter plots identified 244
differentially modulated genes between THP-treated and
age-matched, NS-treated rats (FDR < 0.05 and FC > |2.1|)
(Fig. 4a). Of these 244 genes, 68 (47 %) were upregu-
lated, and 176 (53 %) downregulated (the THP-treated
group show reduced genetic expression levels compared
with the NS group). These differentially expressed genes
were subjected to pathway analysis using a MAS func-
tional annotation tool (http://bioinfo.capitalbio.com/
mas3) and enriched genes examined by GO and KEGG
molecular pathway analyses.
The top ten biological process terms associated with
the highest statistical significance by GO pathway ana-
lyses are listed in Additional file 1: Table S1. GO path-
way analysis of the 176 downregulated genes showed
that the most significant affected population was antigen
processing and presentation (P = 2.12E−37). In particular,
the GO term indicated by cellular component that
showed MHC class I protein complex had the highest
significance of all 23 genes (Table 2), as well as the
KEGG showed by signaling pathway analysis in Fig. 4b.
And KEGG signaling pathway analysis revealed that in
THP-treated rats, a significant number of pathways were
related to graft-versus-host disease, allograft rejection,
and autoimmune thyroid disease as shown in (Add-
itional file 2: Table S2). It was notable that several
MHC-related genes (e.g., RT1-CE12, CD74, RT1-Aw2,
and Mr1) are clearly downregulated because these genes
are grouped in the immune response and antigen pro-
cessing and presentation and neuroimmune/neuroinflam-
matory functions functional clusters (Additional file 1:
Table S1; Additional file 2: Table S2). Both are crucial
components of antigen processing and presentation and
were significantly different between THP- and NS-
treated, age-matched rats. Other highly statistically sig-
nificant differences among the regulated genes were
found for neurotransmitter transport and neuroactive
ligand-receptor interaction (Additional file 1: Table S1;
Fig. 4 Long-term THP treatment recruits distinct gene expression profiles. a Scatterplot of hybridizing signal intensity on DNA microarray. Genetic
scatterplot showing differentially regulated hippocampal genes compared with age-matched, NS-treated animals after long-term THP treatment.
The X and Y axes represent fluorescence intensities of Cy3 and Cy5 signals, respectively. Every spot corresponds to the cross-fertilization signal of
one gene. Red represents upregulation while green shows downregulation. b Gene transcription profiling reveals functional categories regulated
by THP in the hippocampus of aging rats, perculair for MHC class I complex with the highest significance as shown in green circle area. And c only
one common transcript Lpl correlated with Alzheimer’s disease was found and differentially regulated by THP, but less significantly (P = 0.5843).
These functional pathways were derived from KEGG database analyses
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Additional file 2: Table S2), including Oxt, Adra1b, Tac1,
Mas1, and Nts. These were grouped together under
neuroactive ligand-receptor interaction and neuro-
logical system process functional clusters (P = 9.55E−05).
Overall, the neurological system processing and neu-
roimmune/neuroinflammatory dysfunction appears to
be associated with pathological processes induced by
THP. Unexpectedly, we noted that only one common
transcript, Lpl (Fig. 4c), correlated with Alzheimer’s
disease and was differentially regulated, albeit less sig-
nificantly (P = 0.5843), using KEGG pathway analysis.
To confirm our gene expression profiling data ob-
tained by microarray, we performed qRT-PCR using
six selected MHC-relative genes (H2-Ea, Mr1, Cd74,
RT1-CE12, COL1a2, and RT1-AW2). Gene expression
levels of RT1-AW2, H2-Ea, MR1, Cd74, RT1-CE12,
and COL1a2 were significantly decreased compared
with NS-treated, age-matched rats (Fig. 5b; &P < 0.05,
&&P < 0.01, &&&P < 0.001), thereby corroborating our
microarray results. Furthermore, expression of MHCI
protein in the hippocampus and cortex was investi-
gated by immunofluorescence confocal analysis. Com-
pared with age-matched, NS-treated rats, the number
of MHCI-positive cells was significantly decreased in
the hippocampus and cortex after THP treatment
(Fig. 5a).
Tau neurodegeneration appears in the brain of rats with
long-term THP exposure
Neurofibrillary pathology was detected in the brain by
Gallyas silver staining and immunodetection with
monoclonal anti-AT270 antibody, which recognizes tau
protein phosphorylated at Thr181 (Fig. 6a). In younger
rats (i.e., 3-month-old rats), scanty AT270-positive im-
munoreactivity and less silver-positive neurofibrillary
tangles were detected in the somatodendritic compart-
ment of the hippocampal neurons. Compared with age-
matched, NS-treated rats, more silver-positive staining
with a significantly higher number of AT270-positive
neurofibrillary tangles was detected in the brain of rats
following long-term THP exposure (Fig. 6a). Similarly,
Western blot analysis revealed a significant increase in
AT8 and AT270 immunoreactivity in the brain of THP-
treated rats (F = 70.63, P < 0.0001) (Fig. 6b, c).
To determine if the hippocampal neurodegeneration is
induced following long-term THP exposure, we used
FJB as a fluorescent marker for neurodegeneration, in
combination with neuronal marker NeuN staining.
Double-labeling studies showed an overlapping regional
distribution of NeuN and FJB immunoreactivity in the
hippocampus (Fig. 7a). Compared with age-matched,
NS-treated rats, THP-treated rats exhibited slightly in-
creased FJB-labeled cells in selected brain section areas
(F = 2.537, P < 0.05) (Fig. 7b), showing that long-term
THP exposure induces neurodegeneration in aging rats.
Long-term THP exposure affects neuroinflammatory
patterns in rats
In the brain, extensive inflammation mediated by react-
ive microglia was observed using antibodies against IBa1
and CD11b to label microgliosis and activated microglia,
respectively. In THP-treated rats, baseline level activity
Table 2 List of the top five cellular components related to different gene expression between the THP-treated and NS-treated aging
rat index by the GO cellular component term
GO term Count Protein p value q value
MHCI complex
(MHCI)
23 RT1-Aw2; RT1-149; ENSRNOP00000047071; Q6MG05_RAT; RT1-CE10; ENSRNOP00000057803;
Q6MG34_RAT; Q861Q3_RAT; ENSRNOP00000041900; Q6MGB8_RAT; ENSRNOP00000047152;
Q6MGB9_RAT; Q6MG28_RAT; RT1-Cl; RT1-CE14; Q9JHM2_RAT; RT1-Aw2; XP_001070321;
Q6MG29_RAT; Rt1.aa; XP_001072758; Q6MG32_RAT; Q861Q4_RAT; XP_001052972
1.04E−37 1.28E−35
Extracellular region 40 Mgp; Igf2; Anxa2; Bgn; Lgals1; Igfbp2; Fmod; Lum; Ptgds; Penk; Dpp4; Oxt; Gdf10; Cartpt; Tac1;
Col1a2; Fn1; DEF3B_RAT; Q6MG90_RAT; C4; Col3a1; Nid1; Rbp4; Serping1; Aebp1;
ENSRNOP00000046622; Frzb; Cbln1; Kazald1; Klk8; Omd; Avp; Col1a2; Cklf; Cklf; Bmp6; Ccl6;
Bmp7; Timp3; Cxcl13; Nts; Chrdl1
1.22E−33 5.09E−32
Extracellular space 20 Lgals1; Ptgds; Lcat; Oxt; Cp; Cp; Cp; Gdf10; Cartpt; Ada; Col1a2; DEF3B_RAT; Q6MG90_RAT; C4;
Rbp4; Serping1; Klk8; Lpl; Col1a2; Cklf; Cklf; Bmp6; Ccl6; Bmp7
1.15E−23 2.81E−22
Myosin 14 Myh11; ENSRNOP00000047484; XP_001053321; XP_001053402; XP_001053536; XP_001073030;
XP_001072354; XP_001078110; XP_001076239; XP_576790; XP_001072168; XP_576882;
XP_001065390
6.34E−21 1.12E−19
Membrane 51 Ptgds; Slc13a3; Dab2; Enpep; Thbd; Trpc4; ENSRNOP00000052645; ENSRNOP00000052642;
ENSRNOP00000052641; ENSRNOP00000052640; ENSRNOP00000052638; ENSRNOP00000052636;
ENSRNOP00000008172; ENSRNOP00000052635; Ada; Pln; RT1-Da; ENSRNOP00000003349;
Colec12; XP_001061172; MGC108823; XP_574157; Thbd; Fmo1; Cklf; Cklf; ENSRNOP00000058354;
INIB_RAT; RT1-Aw2; RT1-149; ENSRNOP00000047071; Q6MG05_RAT; RT1-CE10;
ENSRNOP00000057803; Q6MG34_RAT; Q861Q3_RAT; ENSRNOP00000041900; Q6MGB8_RAT;
ENSRNOP00000047152; Q6MGB9_RAT; Q6MG28_RAT; RT1-Cl; RT1-CE14; Q9JHM2_RAT; RT1-Aw2;
XP_001070321; Q6MG29_RAT; Rt1.aa; XP_001072758; Q6MG32_RAT; Q861Q4_RAT; XP_001052972;
Clic2; ENSRNOP00000001372
2.89E−14 3.59E−13
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of microglia was minimal and hardly visible in younger
rat brain after IBa-1 and CD11b immunocytochemical
staining. IBa-1 and CD11b labeling of microglia was en-
hanced in the hippocampus and cortex of NS-treated,
aging rats (Fig. 8a, b). Moreover, we found that this en-
hanced microglia response positively correlated with the
rat’s THP-treated brain, with all dosed groups showing
increased microglial numbers and morphological evi-
dence of activation (thick shortened processes, round-
shaped cell parts positive for CD68 (lysosomal mem-
brane glycoprotein) indicate putative phagocytosis and
cell cluster formation) (Fig. 9a, c). Long-term THP treat-
ment increased microglial expression of the activation
marker, CD11b and CD68, in the cortex (Figs. 8a and
9a) and hippocampus (Figs. 8b and 9b). At the same
time, immunoblotting revealed significant upregulation
of CD11b and CD68 levels in THP-treated aging rats
(Fig. 8c, d). Thus, these data suggest that THP-primed
Fig. 5 Alterations in MHC-related genes and MHCI protein induced by long-term THP treatment. a Confocal analysis of THP-treated aging brains
revealed decreased MHCI-positive cells. Scale bar = 50 μm. b qRT-PCR revealed mRNA encoding MHC genes (H2-Ea, MR1, Cd74, RT1-CE12), and
COL1a2 is significantly downregulated by THP in the hippocampus (mean ± SD, n = 3). *P < 0.05, **P < 0.01 compared with the younger group
(3 months old); &P < 0.05, &&P < 0.05 compared with the NS-treated aging group (Dunnett’s test)
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Fig. 6 Qualitative and quantitative profiles of neurofibrillary pathology in rats after long-term THP treatment. a Neurofibrillary tangles stained by
Gallyas silver staining in the hippocampus and immunolabeling with antibody AT270 recognizing tau phosphorylated at Thr181. Gallyas silver
staining revealed more silver-positive staining with a enhanced expression profile of AT270-positive neurofibrillary tangles in the brain of rats with
long-term THP exposure. b Neurofibrillary pathology was quantified by western blot analysis in the prefrontal cortex as a brain region of interest.
c Qualitative analysis revealed significantly upregulated AT8 and AT270 expression in THP-treated aging rats compared with the NS-aging group.
*P < 0.05, ***P < 0.0001 compared with the younger group (3 months old); &P < 0.05, &&&P < 0.0001 compared with the NS-treated group
(Dunnett’s test). Scale bars = 20 μm
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hippocampal and cortical microglia undergo an inflam-
matory phenotypic switch. Two-way ANOVA found that
the THP-treated factor creates approximately 92.04 % of
variability in microglial activation (F = 214.28, P < 0.001)
compared with control rats.
Notably, our immunofluorescence assays revealed
significant upregulation of M1 muscarinic receptor ex-
pression co-localized with CD68, which was mainly
distributed on microglia/macrophages in THP-treated
aging rats (Fig. 9a–c). Stereological quantification re-
vealed the same tendency, with upregulated M1 (t = 10.37,
P < 0.0001) and CD68 (t = 12.12, P < 0.0001) in the brain
cortex of THP-treated aging rats compared with the age-
matched NS group (Fig. 9d). These results indicate direct
modulation of THP on activated microglia-linked M1
receptors.
Discussion
Experimental and clinical studies consistently show that
cholinergic system dysfunction has a detrimental impact
on cognitive performance. Clinical studies suggest that
AC agents may produce cognitive side effects among
older adults, and duration of AC administration has
been described as a risk factor for the appearance of de-
mentia in PD patients. The putative mechanisms may be
associated with dysregulation of cholinergic neurotrans-
mission, thereby leading to memory impairments.
Nevertheless, the exact mechanisms remain unclear.
Here, we report novel findings that long-term THP
administration disrupts neuroimmune signaling, with
transcriptional activity of antigen processing and presen-
tation noticeably downregulated in the hippocampus of
rats. Additionally, we found exacerbated neuroinflamma-
tion with misfolded tau protein pathology related to
neurodegeneration.
Aging is a multifactorial process that leads to altered
behavioral function, including learning and memory.
Here, we assessed AC treatment duration as a risk factor
for cognitive performance, with THP administration for
more than 7 months in aging rats. Thus, we assessed be-
havioral performance of NS-aging and THP-treated,
aging rats in the MWM and open field tasks. The
MWM is a task that is commonly used to assess rodents’
spatial learning and memory ability, and the normal
function of the hippocampus is essential for this task
[17, 18]. In the present study, animals were tested in
Fig. 7 Confocal microscopy revealed hippocampal neurodegeneration in rats after long-term THP treatment. Hippocampal neuronal loss and
neurodegeneration were detected using NeuN and FJB, fluorescent markers for neurons and neurodegeneration, respectively. a Confocal microscopy
shows colocalization of some neurons with neurodegeneration. Scale bar = 50 μm. b Integrated immunofluorescence density analysis was performed
using ImageJ. THP-treated rats show slightly increased FJB-labeled cells in selected hippocampal areas. *P < 0.05 compared with the NS-treated aging
controls (Student’s t test)
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place navigation and probe trials. It should be noted that
only rats treated with THP (1.0 mg/kg, IP) displayed a
significantly poor performance in spatial tasks during
the initial 3-month training session, in which escape la-
tency was significantly disrupted. It is known that THP
acts as a muscarinic receptor antagonist, and muscarinic
acetylcholine receptors play key roles in facilitating cog-
nitive processes. This impairment is consistent with sev-
eral studies using nonselective muscarinic receptor
antagonists to block cholinergic signaling in aging and
AD rodent models [19, 20]. However, we did not find
memory disruption among THP-dosed and NS age-
Fig. 8 Qualitative profile of activated microglia in the rat brain after long-term THP treatment. a and b show IBa1 and CD11b expression in the
cortex and hippocampus, respectively. In animals following long-term THP treatment, microglia increased in number (IBa1) and became activated
(CD11b), with altered morphology and upregulated CD11b. Scale bar = 50 μm. c, d Activated microglia were quantified by Western blot analysis
of cortical CD11b and CD68 expression. &P < 0.05, &&&P < 0.0001 compared with the NS-treated group (Dunnett’s test)
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matched groups upon repetition of MWM training fol-
lowing subsequent treatments, with escape latency or
swimming speed showing no significant impairment.
Moreover, after the final place navigation training, all
tested groups generated similar path length percentages
during the probe task, while the THP (0.5 mg/kg) group
spent significantly more time in the target quadrant of
the apparatus compared with the other two groups. The
probe data confirm that memory disruption is only
present early on in THP treatment. In addition, after the
MWM test, THP- and NS-treated rats showed no sig-
nificant behavioral discrepancies in the open field test.
THP and the behavioral deficit in memory retrieval at
the start of place navigation may reflect its acute func-
tion in blocking muscarinic receptors.
Using microarray analysis, the global impact of THP
on the hippocampal gene expression was examined. GO
and KEGG pathway analysis showed that the most sig-
nificantly affected GO category for long-term THP
treatment was immune response and antigen processing
and presentation or neuroimmune/neuroinflammatory
functions. In particular, genes related to the function of
the MHC class I protein complex were significantly
downregulated (Table 2 and Fig. 4b). These data were
verified by qRT-PCR and confocal-immunofluorescence
analyses, with MHC-related genes and MHCI expression
significantly downregulated in the rat brain (Fig. 5a, b).
Hence, our microarray findings show that long-term
THP treatment suppresses innate and adaptive immune
homeostasis in laboratory animals. This indicates that
THP may function either directly or indirectly in several
immune responses and neuroinflammation.
Next, we found that subchronic THP exposure could
prime pronounced neuroimmune/neuroinflammatory dys-
function and neuronal phenotypic changes. Neuroinflam-
matory abnormalities represent a key difference between
THP- and NS-treated, age-matched rats. Specifically, THP-
treated rats display significantly more Iba1- and CD11b-
positive cells of phagocytic morphology compared with
age-matched NS-treated littermates. Immunoblotting con-
firmed the increase in CD11b- and CD68-positive cells as-
sociated with long-term systemic THP challenge.
Fig. 9 Increased M1 muscarinic receptor expression on activated microglia in the rat brain after long-term THP treatment. Portions of round-shaped
cells are positive for CD68 (lysosomal membrane glycoprotein), indicating putative phagocytosis (a–c). The number of CD68 or M1-positive cells was
stereologically quantified in the prefrontal cortex as a region of interest (d). Compared with NS-treated aging controls, stereological analysis revealed a
significantly higher number of CD68 cells in THP-treated rats. There is also a tendency of increased M1 expression co-localized with CD68 on activated
microglia in the rat cortex after long-term THP treatment (c, d). Scale bar = 50 μm (a, b); scale bar = 10 μm (c). ***P < 0.0001, compared
with the NS-treated aging controls (Student’s t test)
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Notably, our current study shows that in activated
microglia, THP specifically upregulates M1 muscarinic
receptor expression, with a concomitant increase in
CD68 (Fig. 9c). THP is widely used as a nonselective
muscarinic antagonist and inhibits acetylcholine trans-
mission via blockage of mAChRs [7, 8]. Our current
findings suggest that long-term THP use may upregulate
muscarinic M1 receptor expression on microglia, and
thereby play a role in stimulating phenotypic changes in
microglia. Although we cannot exclude the involvement
of other muscarinic receptor types in the observed THP
effects on microglia, our results support our previous
links between cholinergic modulation and the immune
system and inflammation.
Involvement of inflammation is considered to be an
important factor in resistance variability or susceptibility
to AD [21, 22]. Here, we found different alterations in
tau pathology spreading in an AD-like manner. In nor-
mal young rat brain (3 months old), there was less tau
hyperphosphorylation and neurofibrillary tangles. Not-
ably, rats with subchronic THP exposure showed vulner-
ability to neurofibrillary degeneration with misfolded tau
protein aggregation compared with NS-treated, age-
matched rats. Stereological quantification and immuno-
blotting revealed higher levels of phosphorylated tau
AT8 and AT270 changes in THP-treated rats compared
with age-matched controls. Long-term THP also acceler-
ated a mature neurofibrillary pathology and neurodegen-
eration in neurons, and further, confirmed by Gallyas
silver and FJB staining in the hippocampus of rat brain.
Our study supports the hypothesis that long-term THP
exposure affects the progression of neurodegeneration in
these aging animals.
Despite the evidence described above, neurofibrillary
degeneration coupled with an inflammatory response is
not consistent with the cognitive behavioral perform-
ance. Our study shows that cognitive performance is dis-
rupted as an acute impairment and is only present early
on in THP treatment, likely as a consequence of cholin-
ergic signaling blockage because of AC activity. Notably,
this behavioral deficit did not continue or exacerbate
upon repeated behavioral tests with subsequent THP
treatment. Indeed, performances in the MWM and open
field tests suggest that chronic THP exposure could lead
to adaptation alteration or may be a compensatory
mechanism to support cognitive performance, even with
loss of neuronal activity. Accordingly, our study supports
the hypothesis that THP impacts on the pathogenesis
of neurodegeneration in laboratory animals. However,
the neuropathological alterations related to these ad-
aptations have yet to be confirmed. Additionally, our
current study indicated THP-induced neuroimmune/
neuroinflammatory dysfunction may be an event lead-
ing to earlier AD development. The neurodegenerative
neurofibrillary pathogenesis that results from THP ad-
ministration might be an earlier event according to
the performance in behavioral tests. Moreover, there
has been no systematic confirmation that acute or
chronic prescription of such medications leads to
transient or permanent adverse cognitive outcomes.
Several gaps remain in the existing literature on the
previously described association between AC use and
clinical cognitive function. The mechanisms of action
of medications determined in previous studies are in-
consistent, making generation of a comprehensive,
clinically useful list of AC medications impractical
based on those data sets [23, 24]. Thus, understanding
such processes is vital because most drug therapies in-
volve chronic AC administration. Our current study is
the first to comprehensively measure the cognitive impact
of long-term AC exposure on AD in aged laboratory ani-
mals. Neuroimmune/neuroinflammatory dysfunction is
presented as one of the key differences between THP- and
age-matched, NS-treated aging rats, accompanying dele-
terious neurodegenerative progression. AD is the most
common form of dementia in the older population and is
characterized by progressive neurodegeneration of the
CNS. While the precise etiology of this disease still
remains unknown, it is believed that intracellular accumu-
lation of hyperphosphorylated tau (which forms neurofib-
rillary tangles) and deposition of extracellular filaments
play a critical role in neurodegeneration. Accordingly, tau
pathologies are evident in AD [21, 25, 26]. From a mo-
lecular perspective, AD is a multifactorial disorder involv-
ing the association of genetic and environmental factors.
Onset and progression of AD may be influenced by sev-
eral risk factors such as hypertension, metabolic disorders,
and/or inflammatory status [27–29]. Owing to the limita-
tions of our study, we cannot clarify the nature of interac-
tions among THP, CNS inflammatory compartments, and
neuronal neurodegeneration in this model. Future studies
are necessary to determine how THP induces switching of
systemic inflammatory events and progression of neurode-
generative pathology. Furthermore, additional studies
examining the mechanism by which THP exerts its effects
in more commonly used AD models should be performed.
Nonetheless, our current results, together with the litera-
ture, provide clear implications for the rational use of ACs
in older patients.
Conclusions
In summary, to our knowledge, this is the first study to
clearly show that long-term THP treatment impacts on
genes related to immune response pathways, particularly
antigen presentation, and propagates neuroimmune/neu-
roinflammatory dysfunction. Our findings indicate that a
potential mechanism of THP relates to its effects on sev-
eral aspects of the immune response, either directly or
Huang et al. Journal of Neuroinflammation  (2016) 13:175 Page 14 of 16
via neuroimmune pathways. These effects may play a
role in modulating the progression of AD and related
neurodegenerative disorders.
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